Aspen chair Kuseni Dlamini to step down after December 2026 AGM

Aspen Pharmacare Holdings, the South Africa–based multinational drugmaker led by billionaire Stephen Saad, has announced that its chairperson, Kuseni Dlamini, will step down from the board following the company’s annual general meeting (AGM) scheduled for December 2026, marking a significant leadership transition at one of Africa’s largest pharmaceutical companies.

Kuseni Dlamini, who joined the board in 2012 and has served as chair since 2015, confirmed he will not stand for re-election at the AGM. His departure will bring to a close more than a decade of leadership, during which he played a central role in strengthening governance structures amid a turbulent 2025 marked by regulatory setbacks and a costly mRNA contract dispute that erased over $1.2 billion in Aspen’s market value.

Leadership transition at Aspen board

Aspen confirmed that Ben Kruger will succeed Kuseni Dlamini as chair following the AGM. Kruger, who joined the board in 2019, currently serves as Lead Independent Director and has previously chaired the Audit and Risk Committee.

As part of the transition, Kruger will step down from the Audit and Risk Committee upon assuming the chairmanship and has been appointed to the Remuneration and Nomination Committee. The company said further announcements will follow regarding the appointment of a new Lead Independent Director.

The structured succession plan reflects Aspen’s focus on maintaining governance continuity while refreshing leadership at board level.

Board changes and long-serving director retirement

In a parallel development, non-executive director Chris Mortimer will also retire at the conclusion of the AGM after deciding not to stand for re-election.

Mortimer has served on Aspen’s board since 1999, contributing nearly three decades of institutional knowledge and strategic input. Over his tenure, he held roles across multiple board committees and was widely recognized for providing legal counsel and long-term guidance during the company’s growth trajectory.

The board expressed appreciation for his contributions, highlighting his role in supporting Aspen’s development from its early years into a major pharmaceutical group.

Aspen reports softer H1 2026 performance

The leadership transition comes amid a softer financial performance for the first half of 2026. Aspen reported revenue of R21.1 billion ($1.3 billion), representing a 4% year-on-year decline, while normalized EBITDA fell 13% to R5.05 billion ($309.37 million).

Operating profit dropped 31% to R2.7 billion ($165.4 million), weighed down by R695 million ($42.58 million) restructuring costs linked to its manufacturing overhaul. Gross profit declined 8% to R9.58 billion ($586.86 million), with margins impacted by currency headwinds and changes in product mix.

On the balance sheet, total assets declined from R136.6 billion to R128 billion, largely due to asset reclassification tied to the planned APAC divestment. Additional pressure came from compliance issues after a key production facility failed to meet standards set by the U.S. Food and Drug Administration in 2025, further denting investor confidence. During those hurdles, the management, including Stephen Saad, chairman Kuseni Dlamini, among others, stood firmly behind the pharma company.

End of an era in Aspen leadership

Kuseni Dlamini’s exit marks the end of a significant chapter in Aspen’s governance history. Beyond Aspen, he remains a prominent figure in South Africa’s corporate landscape, serving in leadership roles across multiple sectors including retail, mining and financial services.

Aspen acknowledged his “exemplary leadership and steadfast commitment,” crediting him with helping shape the company’s governance framework and long-term strategic direction. While Aspen has not indicated major strategic shifts tied to the board changes, the succession plan signals a measured transition designed to preserve stability while introducing refreshed leadership.

As the company navigates a complex global pharmaceutical environment, effective governance and disciplined execution will remain central to its next phase of growth under new board leadership.